PH30747A - Combination therapy for the treatment of estrogen sensitive disease. - Google Patents
Combination therapy for the treatment of estrogen sensitive disease.Info
- Publication number
- PH30747A PH30747A PH40166A PH40166A PH30747A PH 30747 A PH30747 A PH 30747A PH 40166 A PH40166 A PH 40166A PH 40166 A PH40166 A PH 40166A PH 30747 A PH30747 A PH 30747A
- Authority
- PH
- Philippines
- Prior art keywords
- inhibitor
- treatment
- secretion
- combination therapy
- sensitive disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32192689A | 1989-03-10 | 1989-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PH30747A true PH30747A (en) | 1997-10-17 |
Family
ID=23252650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH40166A PH30747A (en) | 1989-03-10 | 1990-03-09 | Combination therapy for the treatment of estrogen sensitive disease. |
Country Status (17)
Country | Link |
---|---|
US (1) | US5550107A (es) |
EP (1) | EP0462189B1 (es) |
JP (1) | JP2959838B2 (es) |
AT (1) | ATE128362T1 (es) |
AU (2) | AU5281990A (es) |
CA (1) | CA2050291C (es) |
DE (1) | DE69022722T2 (es) |
DK (1) | DK0462189T3 (es) |
ES (1) | ES2077675T3 (es) |
HU (1) | HU221589B (es) |
IE (1) | IE62715B1 (es) |
IL (1) | IL93693A (es) |
MY (1) | MY110016A (es) |
NZ (2) | NZ244499A (es) |
PH (1) | PH30747A (es) |
WO (1) | WO1990010462A1 (es) |
ZA (1) | ZA901847B (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5204337A (en) * | 1988-10-31 | 1993-04-20 | Endorecherche Inc. | Estrogen nucleus derivatives for use in inhibition of sex steroid activity |
US5686465A (en) * | 1988-10-31 | 1997-11-11 | Endorecherche Inc. | Sex steroid activity inhibitors |
US5393785A (en) * | 1988-10-31 | 1995-02-28 | Endorecherche, Inc. | Therapeutic antiestrogens |
US5595985A (en) * | 1989-03-10 | 1997-01-21 | Endorecherche Inc. | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia |
CA2062792C (en) * | 1989-07-07 | 2006-03-21 | Fernard Labrie | Treatment of androgen-related diseases |
NZ241979A (en) * | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
US6060503A (en) * | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
CN1100541C (zh) * | 1993-01-19 | 2003-02-05 | 恩多研究公司 | 脱氢表雄酮的治疗用途和传送系统 |
US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
US6653297B1 (en) * | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
US5879711A (en) * | 1997-11-07 | 1999-03-09 | Sequeira; Joel A. | Stable antiandrogenic gel composition |
MXPA00008868A (es) * | 1998-03-11 | 2003-04-25 | Endorech Inc | Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso. |
US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
CN1309637A (zh) * | 1998-05-15 | 2001-08-22 | 美国家用产品公司 | 包含2-苯基-吲哚化合物和雌激素制剂的组合物 |
US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
WO1999066915A2 (en) * | 1998-06-23 | 1999-12-29 | Southern Illinois University At Carbondale | Therapeutic applications of estrogenic carboxylic acids |
US8173592B1 (en) | 1999-03-31 | 2012-05-08 | Zentaris Ivf Gmbh | Method for a programmed controlled ovarian stimulation protocol |
US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
AU2004222794B2 (en) * | 1999-06-11 | 2007-03-08 | Watson Pharmaceuticals, Inc. | Non-oral androgenic steroids for women |
TR200200406T2 (tr) * | 1999-06-11 | 2002-06-21 | Watson Pharmaceuticals, Inc. | Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması |
US6187750B1 (en) | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
US6562790B2 (en) | 2000-02-05 | 2003-05-13 | Chein Edmund Y M | Hormone therapy methods and hormone products for abating coronary artery blockage |
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
CZ20024214A3 (cs) | 2000-06-28 | 2003-04-16 | Bristol-Myers Squibb Company | Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití |
US7001911B2 (en) | 2000-06-28 | 2006-02-21 | Bristol-Myers Squibb Company | Fused cyclic modulators of nuclear hormone receptor function |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US6953679B2 (en) | 2000-09-19 | 2005-10-11 | Bristol-Myers Squibb Company | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof |
JP2004510994A (ja) * | 2000-10-06 | 2004-04-08 | バイオメディシンズ,インコーポレイティド | エストロゲン−感受性疾病の処理のための組み合わせ治療 |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
GB2375958B (en) * | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
AU2002259147A1 (en) | 2001-05-08 | 2002-11-18 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
DE10141937A1 (de) * | 2001-08-28 | 2003-03-27 | Alfred Schmidt | Markierung der Aromatase |
IL160065A0 (en) | 2001-09-06 | 2004-06-20 | Schering Corp | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
CA2463626C (en) | 2001-10-17 | 2011-05-24 | Schering Corporation | Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
US20040043938A1 (en) * | 2001-11-06 | 2004-03-04 | Dinesh Purandare | Combination therapy for estrogen-dependent disorders |
PL206962B1 (pl) * | 2001-12-19 | 2010-10-29 | Bristol Myers Squibb Co | Związek heterocykliczny o budowie skondensowanej |
EP1488807A4 (en) | 2002-03-11 | 2009-07-08 | Takeda Pharmaceutical | MEDICAMENTS FOR TREATING SEXUAL HORMONE DEPENDENT DISEASE |
JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
AR036970A1 (es) * | 2002-03-15 | 2004-10-20 | Unimed Pharmaceuticals Inc | Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion |
US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
AU2003290799A1 (en) | 2002-11-18 | 2004-06-15 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
DE60323765D1 (de) | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
GB2400554B (en) * | 2003-04-16 | 2007-04-18 | George Margetts | Treatment of angiotensin II-induced cardiovascular disease |
BRPI0516243C1 (pt) | 2004-10-20 | 2021-05-25 | Endorecherche Inc | uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit |
GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
SI1937276T1 (sl) | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Izboljšani testosteronski gel in postopek uporabe |
WO2007045027A1 (en) | 2005-10-19 | 2007-04-26 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
WO2008019048A1 (en) * | 2006-08-04 | 2008-02-14 | Meditrina Pharmaceuticals | Use of aromatase inhibitors for thining the endometrium or treating menorrhagia |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
GB0722779D0 (en) | 2007-11-20 | 2008-01-02 | Sterix Ltd | Compound |
WO2009075838A2 (en) * | 2007-12-10 | 2009-06-18 | Meditrina Pharmaceuticals, Inc. | Treatment of menorrhagia with aromatase inhibitor |
CN103037862A (zh) | 2010-06-16 | 2013-04-10 | 恩多研究公司 | 治疗或预防雌激素相关疾病的方法 |
CA2965372C (en) | 2014-10-22 | 2023-09-05 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
CN108472302A (zh) | 2015-10-22 | 2018-08-31 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
CN114599369A (zh) | 2019-06-03 | 2022-06-07 | 哈瓦赫治疗有限公司 | 用于递送雄激素剂和芳香酶抑制剂的药物制剂和系统以及使用方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3061616A (en) * | 1958-04-24 | 1962-10-30 | Farmaceutici Italia | Steroids, 6-methyl-17-hydroxy-progesterone and esters thereof, and a process for their preparation |
US3127427A (en) * | 1962-07-17 | 1964-03-31 | Hoffmann La Roche | 10-alkenyl-steroids and process therefor |
CH507249A (de) * | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
DE2438350C3 (de) * | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
US4071622A (en) * | 1976-02-11 | 1978-01-31 | Abbott Laboratories | Treatment of a mammary or DMBA inducible tumor |
DE2617646C2 (de) * | 1976-04-22 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
GB1524747A (en) * | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
DE2658307C2 (de) * | 1976-12-22 | 1979-03-15 | Klinge Pharma Gmbh & Co, 8000 Muenchen | Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
FR2465486A1 (fr) * | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
GB2108486B (en) * | 1981-10-26 | 1986-01-29 | Farmos Group Ltd | Alkane and alkene derivatives and their preparation and use |
US4481190A (en) * | 1982-12-21 | 1984-11-06 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists |
GB8311678D0 (en) * | 1983-04-28 | 1983-06-02 | Ici Plc | Phenol derivatives |
US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
IE58417B1 (en) * | 1984-04-27 | 1993-09-22 | Ici Plc | Chemical derivatives |
GB8410901D0 (en) * | 1984-04-27 | 1984-06-06 | Ici Plc | Phenol derivatives |
US4666885A (en) * | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
DE3586053D1 (de) * | 1984-08-02 | 1992-06-17 | Labrie | Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs. |
US4775660A (en) * | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
US4650787A (en) * | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
CN1021196C (zh) * | 1986-12-29 | 1993-06-16 | 新泽西州州立大学(鲁杰斯) | 透皮雌激素/孕激素药剂单元、系统及方法 |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
-
1990
- 1990-03-09 WO PCT/CA1990/000076 patent/WO1990010462A1/en active IP Right Grant
- 1990-03-09 AT AT90904736T patent/ATE128362T1/de not_active IP Right Cessation
- 1990-03-09 DE DE69022722T patent/DE69022722T2/de not_active Expired - Lifetime
- 1990-03-09 AU AU52819/90A patent/AU5281990A/en not_active Abandoned
- 1990-03-09 JP JP2504858A patent/JP2959838B2/ja not_active Expired - Lifetime
- 1990-03-09 NZ NZ244499A patent/NZ244499A/xx unknown
- 1990-03-09 ES ES90904736T patent/ES2077675T3/es not_active Expired - Lifetime
- 1990-03-09 CA CA002050291A patent/CA2050291C/en not_active Expired - Lifetime
- 1990-03-09 PH PH40166A patent/PH30747A/en unknown
- 1990-03-09 EP EP90904736A patent/EP0462189B1/en not_active Expired - Lifetime
- 1990-03-09 IL IL9369390A patent/IL93693A/xx not_active IP Right Cessation
- 1990-03-09 IE IE84690A patent/IE62715B1/en not_active IP Right Cessation
- 1990-03-09 HU HU847/90A patent/HU221589B/hu unknown
- 1990-03-09 NZ NZ232870A patent/NZ232870A/en unknown
- 1990-03-09 DK DK90904736.7T patent/DK0462189T3/da active
- 1990-03-09 ZA ZA901847A patent/ZA901847B/xx unknown
- 1990-03-10 MY MYPI90000459A patent/MY110016A/en unknown
-
1991
- 1991-11-04 US US07/785,890 patent/US5550107A/en not_active Expired - Lifetime
-
1994
- 1994-01-28 AU AU55131/94A patent/AU669767B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ES2077675T3 (es) | 1995-12-01 |
DE69022722T2 (de) | 1996-05-02 |
IE900846L (en) | 1990-09-10 |
ATE128362T1 (de) | 1995-10-15 |
JP2959838B2 (ja) | 1999-10-06 |
IL93693A0 (en) | 1990-12-23 |
MY110016A (en) | 1997-11-29 |
WO1990010462A1 (en) | 1990-09-20 |
HU902847D0 (en) | 1991-11-28 |
US5550107A (en) | 1996-08-27 |
AU669767B2 (en) | 1996-06-20 |
NZ232870A (en) | 1994-01-26 |
DK0462189T3 (da) | 1995-11-20 |
AU5281990A (en) | 1990-10-09 |
CA2050291C (en) | 2000-12-19 |
IE62715B1 (en) | 1995-02-22 |
EP0462189A1 (en) | 1991-12-27 |
AU5513194A (en) | 1994-04-28 |
NZ244499A (en) | 1999-05-28 |
HUT59836A (en) | 1992-07-28 |
HU221589B (hu) | 2002-11-28 |
DE69022722D1 (de) | 1995-11-02 |
ZA901847B (en) | 1991-10-30 |
JPH04504848A (ja) | 1992-08-27 |
EP0462189B1 (en) | 1995-09-27 |
CA2050291A1 (en) | 1990-09-11 |
IL93693A (en) | 2000-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH30747A (en) | Combination therapy for the treatment of estrogen sensitive disease. | |
Singh et al. | Androgen receptor antagonists (antiandrogens) structure-activity relationships | |
Dowsett et al. | Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin | |
AU5854590A (en) | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia | |
IL94991A (en) | Steroid enzyme inhibitors and / or androgen receptor antagonist, their preparation and pharmaceutical components for the treatment of androgenic diseases | |
Steinbeck et al. | Comparison of the effects of cyproterone, cyproterone acetate and oestradiol on testicular function, accessory sexual glands and fertility in a long-term study on rats | |
EP1297840A3 (en) | Methods for treating sex hormone-dependent conditions with LHRH antagonists | |
Tagnon | Antiestrogens in treatment of breast cancer | |
Lundgren | Progestins in Breast Cancer Treatment: A Reveiw | |
Bogden et al. | Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration | |
Zaccheo et al. | Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats | |
RU2003112974A (ru) | Комбинированная терапия для лечения эстрогенчувствительных заболеваний | |
Nishino et al. | Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1, 4-diene-3, 17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors | |
Wells Jr et al. | Ablative procedures in patients with metastatic breast carcinoma | |
CA2428249A1 (en) | Combination therapy for estrogen-dependent disorders | |
Von Minckwitz et al. | New endocrine approaches in the treatment of breast cancer | |
CA2163878A1 (en) | Agents containing a compound with an anti-androgen effect and a compound with a competitive, progesterone-antagonistic effect | |
Jones et al. | Exemestane: a novel aromatase inactivator for breast cancer | |
Geller | Review of assessment of total androgen blockade as treatment of metastatic prostate cancer | |
CZ293771B6 (cs) | Použití steroidních antagonistů estrogenových receptorů pro výrobu léčiv | |
Bajetta et al. | Second-generation aromatase inhibitors | |
Seifter et al. | Effect of metyrapone and aminoglutethimide on the murine sarcoma (MuSV‐M) and breast adenocarcinoma (C3HBA) | |
Boris et al. | The effects of some progestational steroids on pubertal ovulation in the rat | |
Abshagen | β-Methyl-Digoxin Disposition During Spironolactone Treatment | |
Faure et al. | Clinical experience (up to 40 months) with the LH-RH agonist Buserelin in the therapeutic approach to prostatic cancer |